|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Somi MH, Ghojazadeh M, Bagheri M and
Tahamtani T: Clinicopathological factors and gastric cancer
prognosis in the iranian population: A meta-analysis. Asian Pac J
Cancer Prev. 16:853–857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Son T, Hyung WJ, Kim JW, Kim HI, An JY,
Cheong JH, Choi SH and Noh SH: Anatomic extent of metastatic lymph
nodes: Still important for gastric cancer prognosis. Ann Surg
Oncol. 21:899–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marin JJ, Al-Abdulla R, Lozano E, Briz O,
Bujanda L, Banales JM and Macias RI: Mechanisms of resistance to
chemotherapy in gastric cancer. Anticancer Agents Med Chem.
16:318–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang HC, Kim IJ, Park JH, Shin Y, Ku JL,
Jung MS, Yoo BC, Kim HK and Park JG: Identification of genes with
differential expression in acquired drug-resistant gastric cancer
cells using high-density oligonucleotide microarrays. Clin Cancer
Res. 10:272–284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar R, Kaur M and Silakari O:
Physiological modulation approaches to improve cancer chemotherapya
review. Anticancer Agents Med Chem. 14:713–749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frenzel LP, Patz M, Pallasch CP, Brinker
R, Claasen J, Schulz A, Hallek M, Kashkar H and Wendtner CM: Novel
X-linked inhibitor of apoptosis inhibiting compound as sensitizer
for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with
poor prognosis. Br J Haematol. 152:191–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beuten J, Gelfond JA, Piwkham D, Pollock
BH, Winick NJ, Collier AB III and Tomlinson GE: Candidate gene
association analysis of acute lymphoblastic leukemia identifies new
susceptibility locus at 11p15 (LMO1). Carcinogenesis. 32:1349–1353.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR and Freshney RI: Check your cultures! A list of
cross-contaminated or misidentified cell lines. Int J Cancer.
127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugita H, Iida S, Inokuchi M, Kato K,
Ishiguro M, Ishikawa T, Takagi Y, Enjoji M, Yamada H, Uetake H, et
al: Methylation of BNIP3 and DAPK indicates lower response to
chemotherapy and poor prognosis in gastric cancer. Oncol Rep.
25:513–518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu X, Zhang F, Luo D, Li N, Wang Q, Xu Z,
Bian H, Liang Y, Lu Y, Zheng Q and Gu J: URI promotes gastric
cancer cell motility, survival, and resistance to adriamycin in
vitro. Am J Cancer Res. 6:1420–1430. 2016.PubMed/NCBI
|
|
12
|
Lee JH, Soung YH, Lee JW, Park WS, Kim SY,
Cho YG, Kim CJ, Seo SH, Kim HS, Nam SW, et al: Inactivating
mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol.
202:439–445. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mashima T, Oh-hara T, Sato S, Mochizuki M,
Sugimoto Y, Yamazaki K, Hamada J, Tada M, Moriuchi T, Ishikawa Y,
et al: p53-defective tumors with a functional apoptosome-mediated
pathway: A new therapeutic target. J Natl Cancer Inst. 97:765–777.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Yan P, Jing N and Yang J: LMO1 is a
novel oncogene in colorectal cancer and its overexpression is a new
predictive marker for anti-EGFR therapy. Tumour Biol. 35:8161–8167.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Yang J, Wang J, Guo H and Jing N:
LMO1 is a novel oncogene in lung cancer, and its overexpression is
a new predictive marker for anti-EGFR therapy. Med Oncol.
31:992014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng Y, Zhao G, Zhang S, Nigim F, Zhou G,
Yu Z, Song Y, Chen Y and Li Y: AS1411-induced growth inhibition of
glioma cells by up-regulation of p53 and downregulation of Bcl-2
and Akt1 via nucleolin. PLoS One. 11:e01670942016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reddy TL, Garikapati KR, Reddy SG, Reddy
BV, Yadav JS, Bhadra U and Bhadra MP: Simultaneous delivery of
Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier
for the synergistic treatment of melanoma. Sci Rep. 6:352232016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gil J, Ramsey D, Szmida E, Leszczynski P,
Pawlowski P, Bebenek M and Sasiadek MM: The BAX gene as a candidate
for negative autophagy-related genes regulator on mRNA levels in
colorectal cancer. Med Oncol. 34:162017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu L, Wang Z, He SY, Zhang SF, Luo HJ,
Zhou K, Li XF, Qiu SP and Cao KY: Bax-interacting factor-1 inhibits
cell proliferation and promotes apoptosis in prostate cancer cells.
Oncol Rep. 36:3513–3521. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adefolaju GA, Theron KE and Hosie MJ:
BAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells
exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for
24 hrs. Niger Med J. 56:169–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim EM, Kim J, Park JK, Hwang SG, Kim WJ,
Lee WJ, Kang SW and Um HD: Bcl-w promotes cell invasion by blocking
the invasion-suppressing action of Bax. Cell Signal. 24:1163–1172.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu P, Zhang J, Zhu J, Shi J, Zhu Q and
Gao Y: MiR-429 induces gastric carcinoma cell apoptosis through
Bcl-2. Cell Physiol Biochem. 37:1572–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baker M: RNA interference: From tools to
therapies. Nature. 464:12252010. View
Article : Google Scholar
|
